Skip to content

Study · Not a test of the peptide alone · 2009

2 results

Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience.

Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA26 Jul 2008Cited by 40 (Europe PMC)

PMID18661089 (opens in a new tab)DOI10.1007/s00198-008-0698-8 (opens in a new tab)PepBankPUB-18661089
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther

    In osteoporotic women in an education program, persistence with teriparatide was 81.5% at 15 months.

    In plain wordsIn women with osteoporosis in an education program, 81.5% continued teriparatide at 15 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableTreatment persistence at 15 months
    Study

    n = 5,413

    Outcome group
    Treatment adherence and retention · Whole body

    Measurements

    Persistence rate
    81.5%
    15 months, women in the education and follow-up program

    Source sentences

    Summary
    The persistence rate at 15 months was 81.5%, and our analysis suggested that a majority of patients completed the 18-month treatment course.
    2 context sentences
    Summary · context
    This study evaluated the 18-month persistence with teriparatide in 5413 postmenopausal osteoporotic women who were enrolled in an education and follow-up program.
    Summary · context
    Persistence is defined as the percentage of patients still on treatment at the end of the 18-month course, and it has been compared to the data provided by the French universal health insurance system.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome

    In osteoporotic women in the teriparatide education program, adverse events accounted for 46.7% of discontinuations.

    In plain wordsIn women in the teriparatide education program, adverse events accounted for 46.7% of treatment discontinuations.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableAdverse events as reason for discontinuation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Measurements

    Adverse events as share of discontinuations
    46.7%
    Main reason for discontinuation, women in the education and follow-up program

    Source sentences

    Summary
    The main reason for discontinuation was adverse events (46.7%).
    2 context sentences
    Summary · context
    This study evaluated the 18-month persistence with teriparatide in 5413 postmenopausal osteoporotic women who were enrolled in an education and follow-up program.
    Summary · context
    Persistence is defined as the percentage of patients still on treatment at the end of the 18-month course, and it has been compared to the data provided by the French universal health insurance system.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT02472782

Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication

251 Hellenic Air Force & VA General Hospitaln = 851May 2015 to 15 Dec 2018

Osteoporosis, Postmenopausal · Osteoporosis, Steroid Induced

Trial pageClinicalTrials.govUpdated 10 Jan 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.